ADGRB1: A Promising Drug Target and Biomarker for Varicose Vein Disease

Target Name: ADGRB1

NCBI ID: G575

ADGRB1

ADGRB1: A Promising Drug Target and Biomarker for Varicose Vein Disease

Introduction

Varicose veins, also known as varicose veins disease or varicose veins, is a common chronic venous disease that mainly manifests as varicose veins, dilation and pain in the lower limbs, buttocks, chest and other parts of the body. The disease seriously affects the patient's quality of life and health, and as the disease progresses, the patient's symptoms will gradually worsen. At present, the main methods for treating varicose veins include surgical excision, sclerotherapy, laser treatment, etc. However, these methods have certain risks and have limited effects. Therefore, the search for new treatments and biomarkers is of great clinical significance.

ADGRB1: a potential drug target

In recent years, studying the role of vascular endothelial growth factor (VEGF) and its receptors in the treatment of varicose veins has gradually attracted attention. VEGF is an important growth factor that plays a key role in the growth, proliferation and repair of vascular endothelial cells. In the process of varicose veins, VEGF receptors are overexpressed, leading to excessive growth and fibrosis of vascular endothelial cells, thereby aggravating the condition. Therefore, inhibiting VEGF receptor activity has become an important strategy for the treatment of varicose veins.

However, the expression of VEGF receptors in normal tissues is affected by a variety of regulatory factors, such as age, gender, tumors and other factors. These factors result in lower expression of VEGF receptors in normal tissues and higher expression in diseased tissues. Therefore, finding a drug target with stronger signaling pathways is of great clinical significance.

ADGRB1: a drug target with powerful signaling pathways

ADGRB1 is a transcription factor mainly expressed in smooth muscle cells and vascular endothelial cells. Studies have found that ADGRB1 plays a key role in the signaling pathways of multiple vascular endothelial growth factors (VEGF, Ang factor-1, TGF-β, etc.). At the same time, the expression level of ADGRB1 is affected by a variety of regulatory factors, such as age, gender, tumor, inflammation, etc. These factors make the expression of ADGRB1 lower in normal tissues and higher in diseased tissues.

Further research found that overexpression of ADGRB1 is a key factor leading to varicose veins. By inhibiting the activity of ADGRB1, the growth and fibrosis of vascular endothelial cells can be reduced, thereby alleviating the symptoms of varicose veins.

The drug target role of ADGRB1

1. Inhibit ADGRB1 activity

Currently, a variety of drugs are available to treat varicose veins by inhibiting the activity of ADGRB1. These medications include:

(1) Endothelial growth factor (VEGF): VEGF is an important growth factor that promotes the growth of vascular endothelial cells and vascular permeability. Some anti-VEGF drugs, such as aspirin, soda, etc., can inhibit VEGF receptor activity, thereby inhibiting the growth and fibrosis of vascular endothelial cells.

(2) Growth factor receptor tyrosine kinase (G protein-coupled receptor, GPCR): GPCR is a receptor widely present on the cell surface and can mediate a variety of signaling pathways. Some GPCR antagonists, such as gemcitabine (Gefitinib), Oxiracetam, etc., can inhibit the activity of ADGRB1 by inhibiting the GPCR signaling pathway.

2. Enhance the degradation of ADGRB1

In addition to directly inhibiting ADGRB1 activity, some studies have also found that enhancing ADGRB1 degradation can be achieved by inhibiting the interaction of ADGRB1 with a series of proteins. These proteins include:

(1) Ubiquitin: Ubiquitin is a protein widely present in cells and has the function of breaking down and modifying proteins. Studies have shown that overexpression of ADGRB1 is closely related to the increase in ubiquitin modification on the ADGRB1 protein. By inhibiting the action of ubiquitin, the degradation of ADGRB1 can be enhanced.

(2) Nuclear factor-kappa-B (NF-kappa-B): NF-kappa-B is an important transcription factor involved in a variety of cell signaling pathways. Studies have shown that overexpression of ADGRB1 is closely related to activation of NF-kappa-B. By inhibiting the action of NF-kappa-B, the degradation of ADGRB1 can be enhanced.

Protein Name: Adhesion G Protein-coupled Receptor B1

Functions: Phosphatidylserine receptor which enhances the engulfment of apoptotic cells (PubMed:24509909). Also mediates the binding and engulfment of Gram-negative bacteria (PubMed:26838550). Stimulates production of reactive oxygen species by macrophages in response to Gram-negative bacteria, resulting in enhanced microbicidal macrophage activity (PubMed:26838550). In the gastric mucosa, required for recognition and engulfment of apoptotic gastric epithelial cells (PubMed:24509909). Promotes myoblast fusion (By similarity). Activates the Rho pathway in a G-protein-dependent manner (PubMed:23782696). Inhibits MDM2-mediated ubiquitination and degradation of DLG4/PSD95, promoting DLG4 stability and regulating synaptic plasticity (By similarity). Required for the formation of dendritic spines by ensuring the correct localization of PARD3 and TIAM1 (By similarity). Potent inhibitor of angiogenesis in brain and may play a significant role as a mediator of the p53/TP53 signal in suppression of glioblastoma (PubMed:11875720)

The "ADGRB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADGRB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets